Brain reserve and physical disability in secondary progressive multiple sclerosis

BackgroundThe brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced progression of physical disability in patients with...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMJ neurology open Ročník 6; číslo 2; s. e000670
Hlavní autoři:	John, Nevin, Li, Yingtong, De Angelis, Floriana, Stutters, Jonathan, Prados Carrasco, Ferran, Eshaghi, Arman, Doshi, Anisha, Calvi, Alberto, Williams, Thomas, Plantone, Domenico, Phan, Thanh, Barkhof, Frederik, Chataway, Jeremy, Ourselin, Sebastien, Braisher, Marie, Beyene, Tiggy, Bassan, Vanessa, Zapata, Alvin, Chandran, Siddharthan, Connick, Peter, Lyle, Dawn, Cameron, James, Mollison, Daisy, Colville, Shuna, Dhillon, Baljean, Ross, Moira, Cranswick, Gina, Walker, Allan, Smith, Lorraine, Giovannoni, Gavin, Gnanapavan, Sharmilee, Nicholas, Richard, Rashid, Waqar, Aram, Julia, Ford, Helen, Pavitt, Sue H, Overell, James, Young, Carolyn, Arndt, Heinke, Duddy, Martin, Guadagno, Joe, Evangelou, Nikolaos, Craner, Matthew, Palace, Jacqueline, Hobart, Jeremy, Sharrack, Basil, Paling, David, Hawkins, Clive, Kalra, Seema, McLean, Brendan, Stallard, Nigel, Bastow, Roger
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England BMJ Publishing Group Ltd 07.09.2024 BMJ Publishing Group LTD BMJ Publishing Group
Témata:	Age Brain research Cross-sectional studies Dementia Hypotheses MULTIPLE SCLEROSIS NEUROIMMUNOLOGY Original Research Pathology United Kingdom > UK MULTIPLE SCLEROSIS NEUROIMMUNOLOGY
ISSN:	2632-6140, 2632-6140
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	BackgroundThe brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced progression of physical disability in patients with early MS; however, it is unknown whether this association remains once in the secondary progressive phase of MS (SPMS). Our aim was to assess whether larger MLBG is associated with decreased physical disability progression in SPMS.MethodsWe conducted a post hoc analysis of participants in the MS-Secondary Progressive Multi-Arm Randomisation Trial (NCT01910259), a multicentre randomised placebo-controlled trial of the neuroprotective potential of three agents in SPMS. Physical disability was measured by Expanded Disability Status Scale (EDSS), 9-hole peg test (9HPT) and 25-foot timed walk test (T25FW) at baseline, 48 and 96 weeks. MLBG was estimated by baseline intracranial volume (ICV). Multivariable time-varying Cox regression models were used to investigate the association between MLBG and physical disability progression.Results383 participants (mean age 54.5 years, 298 female) were followed up over 96 weeks. Median baseline EDSS was 6.0 (range 4.0–6.5). Adjusted for covariates, larger MLBG was associated with a reduced risk of EDSS progression (HR 0.84,95% CI:0.72 to 0.99;p=0.04). MLBG was not independently associated with time to progression as measured by 9HPT or T25FW.ConclusionLarger MLBG is independently associated with physical disability progression over 96 weeks as measured by EDSS in SPMS. This suggests that MLBG as a proxy for brain reserve may continue to confer protection against disability when in the secondary progression phase of MS.Trail registration numberNCT01910259.
AbstractList	The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced progression of physical disability in patients with early MS; however, it is unknown whether this association remains once in the secondary progressive phase of MS (SPMS). Our aim was to assess whether larger MLBG is associated with decreased physical disability progression in SPMS.BackgroundThe brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced progression of physical disability in patients with early MS; however, it is unknown whether this association remains once in the secondary progressive phase of MS (SPMS). Our aim was to assess whether larger MLBG is associated with decreased physical disability progression in SPMS.We conducted a post hoc analysis of participants in the MS-Secondary Progressive Multi-Arm Randomisation Trial (NCT01910259), a multicentre randomised placebo-controlled trial of the neuroprotective potential of three agents in SPMS. Physical disability was measured by Expanded Disability Status Scale (EDSS), 9-hole peg test (9HPT) and 25-foot timed walk test (T25FW) at baseline, 48 and 96 weeks. MLBG was estimated by baseline intracranial volume (ICV). Multivariable time-varying Cox regression models were used to investigate the association between MLBG and physical disability progression.MethodsWe conducted a post hoc analysis of participants in the MS-Secondary Progressive Multi-Arm Randomisation Trial (NCT01910259), a multicentre randomised placebo-controlled trial of the neuroprotective potential of three agents in SPMS. Physical disability was measured by Expanded Disability Status Scale (EDSS), 9-hole peg test (9HPT) and 25-foot timed walk test (T25FW) at baseline, 48 and 96 weeks. MLBG was estimated by baseline intracranial volume (ICV). Multivariable time-varying Cox regression models were used to investigate the association between MLBG and physical disability progression.383 participants (mean age 54.5 years, 298 female) were followed up over 96 weeks. Median baseline EDSS was 6.0 (range 4.0-6.5). Adjusted for covariates, larger MLBG was associated with a reduced risk of EDSS progression (HR 0.84,95% CI:0.72 to 0.99;p=0.04). MLBG was not independently associated with time to progression as measured by 9HPT or T25FW.Results383 participants (mean age 54.5 years, 298 female) were followed up over 96 weeks. Median baseline EDSS was 6.0 (range 4.0-6.5). Adjusted for covariates, larger MLBG was associated with a reduced risk of EDSS progression (HR 0.84,95% CI:0.72 to 0.99;p=0.04). MLBG was not independently associated with time to progression as measured by 9HPT or T25FW.Larger MLBG is independently associated with physical disability progression over 96 weeks as measured by EDSS in SPMS. This suggests that MLBG as a proxy for brain reserve may continue to confer protection against disability when in the secondary progression phase of MS.ConclusionLarger MLBG is independently associated with physical disability progression over 96 weeks as measured by EDSS in SPMS. This suggests that MLBG as a proxy for brain reserve may continue to confer protection against disability when in the secondary progression phase of MS.NCT01910259.Trail registration numberNCT01910259. The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced progression of physical disability in patients with early MS; however, it is unknown whether this association remains once in the secondary progressive phase of MS (SPMS). Our aim was to assess whether larger MLBG is associated with decreased physical disability progression in SPMS. We conducted a post hoc analysis of participants in the MS-Secondary Progressive Multi-Arm Randomisation Trial (NCT01910259), a multicentre randomised placebo-controlled trial of the neuroprotective potential of three agents in SPMS. Physical disability was measured by Expanded Disability Status Scale (EDSS), 9-hole peg test (9HPT) and 25-foot timed walk test (T25FW) at baseline, 48 and 96 weeks. MLBG was estimated by baseline intracranial volume (ICV). Multivariable time-varying Cox regression models were used to investigate the association between MLBG and physical disability progression. 383 participants (mean age 54.5 years, 298 female) were followed up over 96 weeks. Median baseline EDSS was 6.0 (range 4.0-6.5). Adjusted for covariates, larger MLBG was associated with a reduced risk of EDSS progression (HR 0.84,95% CI:0.72 to 0.99;p=0.04). MLBG was not independently associated with time to progression as measured by 9HPT or T25FW. Larger MLBG is independently associated with physical disability progression over 96 weeks as measured by EDSS in SPMS. This suggests that MLBG as a proxy for brain reserve may continue to confer protection against disability when in the secondary progression phase of MS. NCT01910259. Background The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced progression of physical disability in patients with early MS; however, it is unknown whether this association remains once in the secondary progressive phase of MS (SPMS). Our aim was to assess whether larger MLBG is associated with decreased physical disability progression in SPMS.Methods We conducted a post hoc analysis of participants in the MS-Secondary Progressive Multi-Arm Randomisation Trial (NCT01910259), a multicentre randomised placebo-controlled trial of the neuroprotective potential of three agents in SPMS. Physical disability was measured by Expanded Disability Status Scale (EDSS), 9-hole peg test (9HPT) and 25-foot timed walk test (T25FW) at baseline, 48 and 96 weeks. MLBG was estimated by baseline intracranial volume (ICV). Multivariable time-varying Cox regression models were used to investigate the association between MLBG and physical disability progression.Results 383 participants (mean age 54.5 years, 298 female) were followed up over 96 weeks. Median baseline EDSS was 6.0 (range 4.0–6.5). Adjusted for covariates, larger MLBG was associated with a reduced risk of EDSS progression (HR 0.84,95% CI:0.72 to 0.99;p=0.04). MLBG was not independently associated with time to progression as measured by 9HPT or T25FW.Conclusion Larger MLBG is independently associated with physical disability progression over 96 weeks as measured by EDSS in SPMS. This suggests that MLBG as a proxy for brain reserve may continue to confer protection against disability when in the secondary progression phase of MS.Trail registration number NCT01910259. BackgroundThe brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced progression of physical disability in patients with early MS; however, it is unknown whether this association remains once in the secondary progressive phase of MS (SPMS). Our aim was to assess whether larger MLBG is associated with decreased physical disability progression in SPMS.MethodsWe conducted a post hoc analysis of participants in the MS-Secondary Progressive Multi-Arm Randomisation Trial (NCT01910259), a multicentre randomised placebo-controlled trial of the neuroprotective potential of three agents in SPMS. Physical disability was measured by Expanded Disability Status Scale (EDSS), 9-hole peg test (9HPT) and 25-foot timed walk test (T25FW) at baseline, 48 and 96 weeks. MLBG was estimated by baseline intracranial volume (ICV). Multivariable time-varying Cox regression models were used to investigate the association between MLBG and physical disability progression.Results383 participants (mean age 54.5 years, 298 female) were followed up over 96 weeks. Median baseline EDSS was 6.0 (range 4.0–6.5). Adjusted for covariates, larger MLBG was associated with a reduced risk of EDSS progression (HR 0.84,95% CI:0.72 to 0.99;p=0.04). MLBG was not independently associated with time to progression as measured by 9HPT or T25FW.ConclusionLarger MLBG is independently associated with physical disability progression over 96 weeks as measured by EDSS in SPMS. This suggests that MLBG as a proxy for brain reserve may continue to confer protection against disability when in the secondary progression phase of MS.Trail registration numberNCT01910259.
Author	Mollison, Daisy Stutters, Jonathan Colville, Shuna Craner, Matthew Ford, Helen Braisher, Marie Paling, David Doshi, Anisha Phan, Thanh Hawkins, Clive Smith, Lorraine Palace, Jacqueline Barkhof, Frederik Nicholas, Richard Beyene, Tiggy Gnanapavan, Sharmilee Li, Yingtong Bastow, Roger Arndt, Heinke Guadagno, Joe McLean, Brendan Evangelou, Nikolaos Calvi, Alberto Hobart, Jeremy Dhillon, Baljean Cameron, James Stallard, Nigel Ourselin, Sebastien John, Nevin Overell, James Pavitt, Sue H Ross, Moira Walker, Allan Chataway, Jeremy Bassan, Vanessa Aram, Julia Rashid, Waqar Plantone, Domenico Kalra, Seema Young, Carolyn Prados Carrasco, Ferran Eshaghi, Arman Giovannoni, Gavin Williams, Thomas Chandran, Siddharthan Lyle, Dawn Zapata, Alvin Sharrack, Basil De Angelis, Floriana Connick, Peter Duddy, Martin Cranswick, Gina
Author_xml	– sequence: 1 givenname: Nevin orcidid: 0000-0002-9834-4498 surname: John fullname: John, Nevin email: nevin.john@monash.edu organization: Department of Neurology, Monash Health, Clayton, Victoria, Australia – sequence: 2 givenname: Yingtong orcidid: 0000-0002-0691-0262 surname: Li fullname: Li, Yingtong organization: Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia – sequence: 3 givenname: Floriana orcidid: 0000-0002-9833-1435 surname: De Angelis fullname: De Angelis, Floriana organization: Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK – sequence: 4 givenname: Jonathan surname: Stutters fullname: Stutters, Jonathan organization: Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK – sequence: 5 givenname: Ferran surname: Prados Carrasco fullname: Prados Carrasco, Ferran organization: e-Health Center, Universitat Oberta de Catalunya, Barcelona, Spain – sequence: 6 givenname: Arman surname: Eshaghi fullname: Eshaghi, Arman organization: Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK – sequence: 7 givenname: Anisha surname: Doshi fullname: Doshi, Anisha organization: Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK – sequence: 8 givenname: Alberto orcidid: 0000-0002-1953-2803 surname: Calvi fullname: Calvi, Alberto organization: Advanced Imaging in Neuroimmunological Diseases Lab (ImaginEM), Fundacio Clinic per la Recerca Biomedica, Barcelona, Spain – sequence: 9 givenname: Thomas surname: Williams fullname: Williams, Thomas organization: Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK – sequence: 10 givenname: Domenico orcidid: 0000-0001-6666-7244 surname: Plantone fullname: Plantone, Domenico organization: Department of Medicine, Surgery & Neuroscience, University of Siena, Siena, Italy – sequence: 11 givenname: Thanh surname: Phan fullname: Phan, Thanh organization: Department of Neurology, Monash Health, Clayton, Victoria, Australia – sequence: 12 givenname: Frederik surname: Barkhof fullname: Barkhof, Frederik organization: Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam, The Netherlands – sequence: 13 givenname: Jeremy orcidid: 0000-0001-7286-6901 surname: Chataway fullname: Chataway, Jeremy organization: NIHR University College London Hospitals Biomedical Research Centre, London, UK – sequence: 14 givenname: Sebastien surname: Ourselin fullname: Ourselin, Sebastien – sequence: 15 givenname: Marie surname: Braisher fullname: Braisher, Marie – sequence: 16 givenname: Tiggy surname: Beyene fullname: Beyene, Tiggy – sequence: 17 givenname: Vanessa surname: Bassan fullname: Bassan, Vanessa – sequence: 18 givenname: Alvin surname: Zapata fullname: Zapata, Alvin – sequence: 19 givenname: Siddharthan surname: Chandran fullname: Chandran, Siddharthan – sequence: 20 givenname: Peter surname: Connick fullname: Connick, Peter – sequence: 21 givenname: Dawn surname: Lyle fullname: Lyle, Dawn – sequence: 22 givenname: James surname: Cameron fullname: Cameron, James – sequence: 23 givenname: Daisy surname: Mollison fullname: Mollison, Daisy – sequence: 24 givenname: Shuna surname: Colville fullname: Colville, Shuna – sequence: 25 givenname: Baljean surname: Dhillon fullname: Dhillon, Baljean – sequence: 26 givenname: Moira surname: Ross fullname: Ross, Moira – sequence: 27 givenname: Gina surname: Cranswick fullname: Cranswick, Gina – sequence: 28 givenname: Allan surname: Walker fullname: Walker, Allan – sequence: 29 givenname: Lorraine surname: Smith fullname: Smith, Lorraine – sequence: 30 givenname: Gavin surname: Giovannoni fullname: Giovannoni, Gavin – sequence: 31 givenname: Sharmilee surname: Gnanapavan fullname: Gnanapavan, Sharmilee – sequence: 32 givenname: Richard surname: Nicholas fullname: Nicholas, Richard – sequence: 33 givenname: Waqar surname: Rashid fullname: Rashid, Waqar – sequence: 34 givenname: Julia surname: Aram fullname: Aram, Julia – sequence: 35 givenname: Helen surname: Ford fullname: Ford, Helen – sequence: 36 givenname: Sue H surname: Pavitt fullname: Pavitt, Sue H – sequence: 37 givenname: James surname: Overell fullname: Overell, James – sequence: 38 givenname: Carolyn surname: Young fullname: Young, Carolyn – sequence: 39 givenname: Heinke surname: Arndt fullname: Arndt, Heinke – sequence: 40 givenname: Martin surname: Duddy fullname: Duddy, Martin – sequence: 41 givenname: Joe surname: Guadagno fullname: Guadagno, Joe – sequence: 42 givenname: Nikolaos surname: Evangelou fullname: Evangelou, Nikolaos – sequence: 43 givenname: Matthew surname: Craner fullname: Craner, Matthew – sequence: 44 givenname: Jacqueline surname: Palace fullname: Palace, Jacqueline – sequence: 45 givenname: Jeremy surname: Hobart fullname: Hobart, Jeremy – sequence: 46 givenname: Basil surname: Sharrack fullname: Sharrack, Basil – sequence: 47 givenname: David surname: Paling fullname: Paling, David – sequence: 48 givenname: Clive surname: Hawkins fullname: Hawkins, Clive – sequence: 49 givenname: Seema surname: Kalra fullname: Kalra, Seema – sequence: 50 givenname: Brendan surname: McLean fullname: McLean, Brendan – sequence: 51 givenname: Nigel surname: Stallard fullname: Stallard, Nigel – sequence: 52 givenname: Roger surname: Bastow fullname: Bastow, Roger
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/39262426$$D View this record in MEDLINE/PubMed
BookMark	eNp1kstu1TAQhi3Uil7oA7BBkdiwCfUtTrJCUFGoVKlCgrVlO5NTHyV2sJNK5-2Z05TSInVly_PNP79n5oQchBiAkLeMfmRMqHM7bkMsOeWypJSqmr4ix1wJXiom6cGT-xE5y3mLDK-obFr5mhyJlisuuTomP74k40ORIEO6g8KErphud9k7MxSdz8b6wc-7ApEMLobOpF0xpbjBhOwxYVyG2U8DFNkNkGL2-Q057M2Q4ezhPCW_Lr_-vPheXt98u7r4fF1a2ci5rJW0ojFowyhhBFOqZraV1FHgnRO25wCUN0a0FmzT9opy46QRHQAzfdWLU3K16nbRbPWU_IjedDRe3z_EtNEmzR5taSrqunWVc_htLFe3Sllby16aCnouO9T6tGpNix2hcxDmZIZnos8jwd_qTbzTOImmrliFCh8eFFL8vUCe9eizg2EwAeKStWBUSNk2XCD6_j90G5cUsFd7ismatRVH6t1TS49e_o4OAbYCDtueE_SPCKN7X0rfb4jeb4heNwRzyjUHQ_-qvsz_AR_Lvbk
Cites_doi	10.1212/WNL.0b013e318296e98b 10.1016/j.neuroimage.2016.06.053 10.1016/S0140-6736(13)62242-4 10.1037/0894-4105.7.3.273 10.1109/42.906424 10.1080/00029890.1962.11989827 10.1016/j.neuroimage.2014.09.034 10.1007/s00330-018-5710-x 10.1212/WNL.0000000000012499 10.1186/s13195-018-0408-5 10.1212/CPJ.0000000000001045 10.1016/j.stem.2018.03.015 10.1212/WNL.0000000000002702 10.1136/bmjopen-2018-021944 10.1016/S0140-6736(18)30475-6 10.3390/nu13010199 10.1176/appi.ajp.2019.18080970 10.1001/archneur.1994.00540210046012 10.1212/wnl.49.1.30 10.1002/aja.1001800203 10.1212/WNL.0000000000011123 10.1002/hbm.21260 10.1111/j.1365-3016.2005.00676.x 10.1212/NXI.0000000000000279 10.1212/WNL.0000000000000433 10.1016/j.clnu.2020.11.025 10.1002/ana.410230206 10.1038/nn.4398 10.3389/fnins.2022.825811 10.1006/nimg.2002.1040 10.1016/S1474-4422(19)30485-5 10.1017/S1355617702813248 10.2307/2312726 10.1212/WNL.49.1.30
ContentType	Journal Article
Copyright	Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. 2024
Copyright_xml	– notice: Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. – notice: Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. – notice: 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. 2024
CorporateAuthor	for the MS-SMART Investigators MS-SMART Investigators
CorporateAuthor_xml	– name: MS-SMART Investigators
DBID	9YT ACMMV AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1136/bmjno-2024-000670
DatabaseName	BMJ Open Access Journals BMJ Journals:Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (New) ProQuest Central (Alumni) ProQuest One Academic (New) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed ProQuest One Academic Middle East (New)
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
EISSN	2632-6140
ExternalDocumentID	oai_doaj_org_article_03779c5cc9264a67966bb74f4a5ef24d PMC11387515 39262426 10_1136_bmjno_2024_000670 bmjno
Genre	Journal Article
GeographicLocations	United Kingdom--UK
GeographicLocations_xml	– name: United Kingdom--UK
GrantInformation_xml	– fundername: Efficacy and Mechanism Evaluation Programme grantid: EME 11/30/11 funderid: http://dx.doi.org/10.13039/501100001922 – fundername: ; grantid: EME 11/30/11
GroupedDBID	53G 7X7 8FI 8FJ 9YT ABUWG ACMMV AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR CCPQU EBS FYUFA GROUPED_DOAJ HMCUK M~E OK1 PGMZT RMJ RPM UKHRP AAYXX CITATION PHGZM NPM 3V. 7XB 8FK K9. PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-b484t-764b38a624a63a316671b940c0e2dc3bf2ee028a39beb89f602ac4a3dee1af5f3
IEDL.DBID	DOA
ISICitedReferencesCount	2
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001307836400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2632-6140
IngestDate	Fri Oct 03 12:46:07 EDT 2025 Tue Sep 30 17:07:43 EDT 2025 Sun Sep 28 01:25:46 EDT 2025 Tue Oct 07 07:01:22 EDT 2025 Thu Jan 02 22:42:31 EST 2025 Sat Nov 29 07:42:56 EST 2025 Thu Apr 24 22:50:10 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	MULTIPLE SCLEROSIS NEUROIMMUNOLOGY
Language	English
License	This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-b484t-764b38a624a63a316671b940c0e2dc3bf2ee028a39beb89f602ac4a3dee1af5f3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 NJ and YL are joint first authors. Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/bmjno-2024-000670). NJ is a local principal investigator on commercial MS studies funded by Novartis, Roche and Sanofi. He has received speakers honoraria from Merck and congress sponsorship covering registration and travel from Novartis. FB serves on the editorial boards of Brain, European Radiology, Journal of Neurology, Neurosurgery & Psychiatry, Neurology, Multiple Sclerosis and Neuroradiology, and serves as consultant for Bayer Schering Pharma, Sanofi-Aventis, Biogen-Idec, TEVA Pharmaceuticals, Genzyme, Merck-Serono, Novartis, Roche, Synthon, Jansen Research and Lundbeck. CAGW-K has received research grants (PI and co-applicant) from Spinal Research, Craig H. Neilsen Foundation, EPSRC, Wings for Life, UK MS Society, Horizon 2020, NIHR/MRC, MRC and is a shareholder of Queen Square Analytics. In the last 3 years, JC has received support from the Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by the Canadian MS Society. A local principal investigator for commercial trials funded by: Actelion, Biogen, Novartis and Roche; has received an investigator grant from Novartis; and has taken part in advisory boards/consultancy for Azadyne, Biogen, Celgene, Janssen, MedDay, Merck, NervGen, Novartis and Roche. NJ and YL contributed equally. Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
ORCID	0000-0001-7286-6901 0000-0002-9833-1435 0000-0002-1953-2803 0000-0002-0691-0262 0000-0001-6666-7244 0000-0002-9834-4498
OpenAccessLink	https://doaj.org/article/03779c5cc9264a67966bb74f4a5ef24d
PMID	39262426
PQID	3101471952
PQPubID	5161132
ParticipantIDs	doaj_primary_oai_doaj_org_article_03779c5cc9264a67966bb74f4a5ef24d pubmedcentral_primary_oai_pubmedcentral_nih_gov_11387515 proquest_miscellaneous_3103449823 proquest_journals_3101471952 pubmed_primary_39262426 crossref_primary_10_1136_bmjno_2024_000670 bmj_journals_10_1136_bmjno_2024_000670
PublicationCentury	2000
PublicationDate	2024-09-07
PublicationDateYYYYMMDD	2024-09-07
PublicationDate_xml	– month: 09 year: 2024 text: 2024-09-07 day: 07
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationTitle	BMJ neurology open
PublicationTitleAbbrev	BMJ Neurol Open
PublicationTitleAlternate	BMJ Neurol Open
PublicationYear	2024
Publisher	BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group
Publisher_xml	– name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group
References	Connick, De Angelis, Parker (R13) 2018; 8 Zou, El Marroun, Cecil (R25) 2021; 40 Katzman, Terry, DeTeresa (R8) 1988; 23 Boldrini, Fulmore, Tartt (R19) 2018; 22 Bocancea, van Loenhoud, Groot (R26) 2021; 97 Kappos, Bar-Or, Cree (R30) 2018; 391 Satz (R1) 1993; 7 Malone, Leung, Clegg (R32) 2015; 104 Koch, Mostert, Repovic (R29) 2021; 96 Sumowski, Rocca, Leavitt (R11) 2014; 82 Zou, Tiemeier, van der Ende (R24) 2019; 176 Schofield, Logroscino, Andrews (R5) 1997; 49 (R3) 2022; 16 Stern (R6) 2002; 8 Zhang, Brady, Smith (R16) 2001; 20 Krieger, Cook, De Nino (R27) 2016; 3 Smith, Zhang, Jenkinson (R15) 2002; 17 Engel, Berkowitz, Wolff (R22) 2005; 19 Haug (R7) 1987; 180 Pfefferbaum, Mathalon, Sullivan (R4) 1994; 51 Cohen Kadosh, Muhardi, Parikh (R21) 2021; 13 Prados, Cardoso, Kanber (R14) 2016; 139 Sumowski, Rocca, Leavitt (R10) 2013; 80 Sumowski, Rocca, Leavitt (R2) 2016; 86 Chataway, Schuerer, Alsanousi (R31) 2014; 383 van Loenhoud, Groot, Vogel (R9) 2018; 10 Guo, Ferreira, Fink (R33) 2019; 29 Chataway, De Angelis, Connick (R12) 2020; 19 Roussotte, Sulik, Mattson (R23) 2012; 33 Vollmer, Nair, Williams (R28) 2021; 11 Gale, Shapley (R17) 1962; 69 Adams, Hibar, Chouraki (R20) 2016; 19 Sumowski (2025072812030088000_6.2.e000670.10) 2013; 80 Koch (2025072812030088000_6.2.e000670.29) 2021; 96 2025072812030088000_6.2.e000670.28 van Loenhoud (2025072812030088000_6.2.e000670.9) 2018; 10 2025072812030088000_6.2.e000670.23 2025072812030088000_6.2.e000670.31 Sumowski (2025072812030088000_6.2.e000670.2) 2016; 86 2025072812030088000_6.2.e000670.30 2025072812030088000_6.2.e000670.7 Zou (2025072812030088000_6.2.e000670.25) 2021; 40 2025072812030088000_6.2.e000670.33 2025072812030088000_6.2.e000670.8 Sumowski (2025072812030088000_6.2.e000670.11) 2014; 82 2025072812030088000_6.2.e000670.32 2025072812030088000_6.2.e000670.1 Zou (2025072812030088000_6.2.e000670.24) 2019; 176 2025072812030088000_6.2.e000670.6 2025072812030088000_6.2.e000670.4 Schofield (2025072812030088000_6.2.e000670.5) 1997; 49 Bocancea (2025072812030088000_6.2.e000670.26) 2021; 97 Connick (2025072812030088000_6.2.e000670.13) 2018; 8 2025072812030088000_6.2.e000670.17 2025072812030088000_6.2.e000670.16 2025072812030088000_6.2.e000670.19 2025072812030088000_6.2.e000670.18 2025072812030088000_6.2.e000670.12 2025072812030088000_6.2.e000670.15 Krieger (2025072812030088000_6.2.e000670.27) 2016; 3 2025072812030088000_6.2.e000670.14 2025072812030088000_6.2.e000670.20 2025072812030088000_6.2.e000670.22 (2025072812030088000_6.2.e000670.3) 2022; 16 Cohen Kadosh (2025072812030088000_6.2.e000670.21) 2021; 13
References_xml	– volume: 80 start-page: 2186 year: 2013 ident: R10 article-title: Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it publication-title: Neurol (ECronicon) doi: 10.1212/WNL.0b013e318296e98b – volume: 139 start-page: 376 year: 2016 ident: R14 article-title: A multi-time-point modality-agnostic patch-based method for lesion filling in multiple sclerosis publication-title: Neuroimage doi: 10.1016/j.neuroimage.2016.06.053 – volume: 383 start-page: 2213 year: 2014 ident: R31 article-title: Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(13)62242-4 – volume: 8 start-page: 448 year: 2002 ident: R6 article-title: What is cognitive reserve? Theory and research application of the reserve concept publication-title: J Int Neuropsychol Soc – volume: 7 start-page: 273 year: 1993 ident: R1 article-title: Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence for threshold theory publication-title: Neuropsychology doi: 10.1037/0894-4105.7.3.273 – volume: 20 start-page: 45 year: 2001 ident: R16 article-title: Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm publication-title: IEEE Trans Med Imaging doi: 10.1109/42.906424 – volume: 69 start-page: 9 year: 1962 ident: R17 article-title: College admissions and the stability of marriage publication-title: Am Math Mon doi: 10.1080/00029890.1962.11989827 – volume: 104 start-page: 366 year: 2015 ident: R32 article-title: Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance publication-title: Neuroimage doi: 10.1016/j.neuroimage.2014.09.034 – volume: 29 start-page: 1355 year: 2019 ident: R33 article-title: Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis publication-title: Eur Radiol doi: 10.1007/s00330-018-5710-x – volume: 97 start-page: 474 year: 2021 ident: R26 article-title: Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis publication-title: Neurology (ECronicon) doi: 10.1212/WNL.0000000000012499 – volume: 10 year: 2018 ident: R9 article-title: Is intracranial volume a suitable proxy for brain reserve? publication-title: Alzheimers Res Ther doi: 10.1186/s13195-018-0408-5 – volume: 11 start-page: 342 year: 2021 ident: R28 article-title: Multiple Sclerosis Phenotypes as a Continuum: The Role of Neurologic Reserve publication-title: Neurol Clin Pract doi: 10.1212/CPJ.0000000000001045 – volume: 22 start-page: 589 year: 2018 ident: R19 article-title: Human Hippocampal Neurogenesis Persists throughout Aging publication-title: Cell Stem Cell doi: 10.1016/j.stem.2018.03.015 – volume: 86 start-page: 2006 year: 2016 ident: R2 article-title: Brain reserve against physical disability progression over 5 years in multiple sclerosis publication-title: Neurol (ECronicon) doi: 10.1212/WNL.0000000000002702 – volume: 8 year: 2018 ident: R13 article-title: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis publication-title: BMJ Open doi: 10.1136/bmjopen-2018-021944 – volume: 391 start-page: 1263 year: 2018 ident: R30 article-title: Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study publication-title: Lancet doi: 10.1016/S0140-6736(18)30475-6 – volume: 13 year: 2021 ident: R21 article-title: Nutritional Support of Neurodevelopment and Cognitive Function in Infants and Young Children-An Update and Novel Insights publication-title: Nutrients doi: 10.3390/nu13010199 – volume: 176 start-page: 702 year: 2019 ident: R24 article-title: Exposure to Maternal Depressive Symptoms in Fetal Life or Childhood and Offspring Brain Development: A Population-Based Imaging Study publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2019.18080970 – volume: 51 start-page: 874 year: 1994 ident: R4 article-title: A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood publication-title: Arch Neurol doi: 10.1001/archneur.1994.00540210046012 – volume: 49 start-page: 30 year: 1997 ident: R5 article-title: An association between head circumference and Alzheimer’s disease in a population-based study of aging and dementia publication-title: Neurology (ECronicon) doi: 10.1212/wnl.49.1.30 – volume: 180 start-page: 126 year: 1987 ident: R7 article-title: Brain sizes, surfaces, and neuronal sizes of the cortex cerebri: a stereological investigation of man and his variability and a comparison with some mammals (primates, whales, marsupials, insectivores, and one elephant) publication-title: Am J Anat doi: 10.1002/aja.1001800203 – volume: 96 start-page: e111 year: 2021 ident: R29 article-title: Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis publication-title: Neurology (ECronicon) doi: 10.1212/WNL.0000000000011123 – volume: 33 start-page: 920 year: 2012 ident: R23 article-title: Regional brain volume reductions relate to facial dysmorphology and neurocognitive function in fetal alcohol spectrum disorders publication-title: Hum Brain Mapp doi: 10.1002/hbm.21260 – volume: 19 start-page: 334 year: 2005 ident: R22 article-title: Psychological trauma associated with the World Trade Center attacks and its effect on pregnancy outcome publication-title: Paediatr Perinat Epidemiol doi: 10.1111/j.1365-3016.2005.00676.x – volume: 3 year: 2016 ident: R27 article-title: The topographical model of multiple sclerosis: A dynamic visualization of disease course publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000000279 – volume: 82 start-page: 1776 year: 2014 ident: R11 article-title: Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS publication-title: Neurol (ECronicon) doi: 10.1212/WNL.0000000000000433 – volume: 40 start-page: 3391 year: 2021 ident: R25 article-title: Maternal folate levels during pregnancy and offspring brain development in late childhood publication-title: Clin Nutr doi: 10.1016/j.clnu.2020.11.025 – volume: 23 start-page: 138 year: 1988 ident: R8 article-title: Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques publication-title: Ann Neurol doi: 10.1002/ana.410230206 – volume: 19 start-page: 1569 year: 2016 ident: R20 article-title: Novel genetic loci underlying human intracranial volume identified through genome-wide association publication-title: Nat Neurosci doi: 10.1038/nn.4398 – volume: 16 year: 2022 ident: R3 article-title: Are Brain and Cognitive Reserve Shaped by Early Life Circumstances? publication-title: Front Neurosci doi: 10.3389/fnins.2022.825811 – volume: 17 start-page: 479 year: 2002 ident: R15 article-title: Accurate, robust, and automated longitudinal and cross-sectional brain change analysis publication-title: Neuroimage doi: 10.1006/nimg.2002.1040 – volume: 19 start-page: 214 year: 2020 ident: R12 article-title: Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(19)30485-5 – ident: 2025072812030088000_6.2.e000670.14 doi: 10.1016/j.neuroimage.2016.06.053 – volume: 96 start-page: e111 year: 2021 ident: 2025072812030088000_6.2.e000670.29 article-title: Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis publication-title: Neurology (ECronicon) – volume: 16 year: 2022 ident: 2025072812030088000_6.2.e000670.3 article-title: Are Brain and Cognitive Reserve Shaped by Early Life Circumstances? publication-title: Front Neurosci doi: 10.3389/fnins.2022.825811 – ident: 2025072812030088000_6.2.e000670.4 doi: 10.1001/archneur.1994.00540210046012 – ident: 2025072812030088000_6.2.e000670.23 doi: 10.1002/hbm.21260 – ident: 2025072812030088000_6.2.e000670.7 doi: 10.1002/aja.1001800203 – ident: 2025072812030088000_6.2.e000670.22 doi: 10.1111/j.1365-3016.2005.00676.x – ident: 2025072812030088000_6.2.e000670.6 doi: 10.1017/S1355617702813248 – ident: 2025072812030088000_6.2.e000670.12 doi: 10.1016/S1474-4422(19)30485-5 – ident: 2025072812030088000_6.2.e000670.33 doi: 10.1007/s00330-018-5710-x – ident: 2025072812030088000_6.2.e000670.30 doi: 10.1016/S0140-6736(18)30475-6 – ident: 2025072812030088000_6.2.e000670.31 doi: 10.1016/S0140-6736(13)62242-4 – volume: 80 start-page: 2186 year: 2013 ident: 2025072812030088000_6.2.e000670.10 article-title: Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it publication-title: Neurol (ECronicon) – ident: 2025072812030088000_6.2.e000670.19 doi: 10.1016/j.stem.2018.03.015 – ident: 2025072812030088000_6.2.e000670.17 doi: 10.2307/2312726 – volume: 82 start-page: 1776 year: 2014 ident: 2025072812030088000_6.2.e000670.11 article-title: Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS publication-title: Neurol (ECronicon) – ident: 2025072812030088000_6.2.e000670.32 doi: 10.1016/j.neuroimage.2014.09.034 – volume: 10 year: 2018 ident: 2025072812030088000_6.2.e000670.9 article-title: Is intracranial volume a suitable proxy for brain reserve? publication-title: Alzheimers Res Ther doi: 10.1186/s13195-018-0408-5 – ident: 2025072812030088000_6.2.e000670.20 doi: 10.1038/nn.4398 – volume: 3 year: 2016 ident: 2025072812030088000_6.2.e000670.27 article-title: The topographical model of multiple sclerosis: A dynamic visualization of disease course publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000000279 – ident: 2025072812030088000_6.2.e000670.8 doi: 10.1002/ana.410230206 – volume: 49 start-page: 30 year: 1997 ident: 2025072812030088000_6.2.e000670.5 article-title: An association between head circumference and Alzheimer’s disease in a population-based study of aging and dementia publication-title: Neurology (ECronicon) doi: 10.1212/WNL.49.1.30 – volume: 97 start-page: 474 year: 2021 ident: 2025072812030088000_6.2.e000670.26 article-title: Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis publication-title: Neurology (ECronicon) doi: 10.1212/WNL.0000000000012499 – ident: 2025072812030088000_6.2.e000670.16 doi: 10.1109/42.906424 – ident: 2025072812030088000_6.2.e000670.28 doi: 10.1212/CPJ.0000000000001045 – ident: 2025072812030088000_6.2.e000670.1 doi: 10.1037/0894-4105.7.3.273 – volume: 13 year: 2021 ident: 2025072812030088000_6.2.e000670.21 article-title: Nutritional Support of Neurodevelopment and Cognitive Function in Infants and Young Children-An Update and Novel Insights publication-title: Nutrients doi: 10.3390/nu13010199 – ident: 2025072812030088000_6.2.e000670.18 – volume: 176 start-page: 702 year: 2019 ident: 2025072812030088000_6.2.e000670.24 article-title: Exposure to Maternal Depressive Symptoms in Fetal Life or Childhood and Offspring Brain Development: A Population-Based Imaging Study publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2019.18080970 – volume: 8 year: 2018 ident: 2025072812030088000_6.2.e000670.13 article-title: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis publication-title: BMJ Open doi: 10.1136/bmjopen-2018-021944 – volume: 86 start-page: 2006 year: 2016 ident: 2025072812030088000_6.2.e000670.2 article-title: Brain reserve against physical disability progression over 5 years in multiple sclerosis publication-title: Neurol (ECronicon) – ident: 2025072812030088000_6.2.e000670.15 doi: 10.1006/nimg.2002.1040 – volume: 40 start-page: 3391 year: 2021 ident: 2025072812030088000_6.2.e000670.25 article-title: Maternal folate levels during pregnancy and offspring brain development in late childhood publication-title: Clin Nutr doi: 10.1016/j.clnu.2020.11.025
SSID	ssj0002504894
Score	2.2811463
Snippet	BackgroundThe brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple... The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis... Background The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple...
SourceID	doaj pubmedcentral proquest pubmed crossref bmj
SourceType	Open Website Open Access Repository Aggregation Database Index Database Publisher
StartPage	e000670
SubjectTerms	Age Brain research Cross-sectional studies Dementia Hypotheses MULTIPLE SCLEROSIS NEUROIMMUNOLOGY Original Research Pathology
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELVgy4ELFPEVaCsjIQ5IUZN47NgnxKJWPa0KAqm3yHYc2EokS7Kt1H_PTOLdsgj1wtWeROO8mXhsj98w9jazsvR0OUY1Mkuh9DrVOO2kOQQ6f7TgxVRsolws9MWFOY8bbkNMq9z8E8cfdd152iM_FlRUtsyNLD6sfqVUNYpOV2MJjftsj5jKYMb25ieL8y_bXRYi6NIG4nFmLtSx-3nZdmgbBaTTJRWcVLBtZ1oa2fv_FXL-nTn5x1R0-vh_B7HPHsUglH-crOYJuxfap-zznKpFcLqO1F8HbtuaryKIvI5MvOsbjiIDLaJr29_wMbuLEmnxgU1qIh_wnTjI5fCMfTs9-frpLI0FF1IHGtZpqcAJbVUBVgkrcqXK3BnIfBaK2gvXFCFgPGKFccFp06issB6sqEPIbSMb8ZzN2q4NLxmH0mHkZa3LvMGYz1tpQDYZeC9rFBYJe4dfvYoOM1TjWkSoaoSnIniqCZ6Evd8AU60mAo67hOcE3VaQuLPHhq7_XkVXrDLiWPTSe4PBoKV9NOVcCQ1YGZoC6oQdbMC71e8WuYS92XajK9L5im1DdzXKCACjCxzdi8lOtpoI4mXEaChheseCdlTd7WmXP0a6bxwqLipz-epuvV6zh5NV06W0AzZb91fhkD3w1-vl0B9Fx_gNcUQYBg priority: 102 providerName: ProQuest
Title	Brain reserve and physical disability in secondary progressive multiple sclerosis
URI	https://neurologyopen.bmj.com/content/6/2/e000670.full https://www.ncbi.nlm.nih.gov/pubmed/39262426 https://www.proquest.com/docview/3101471952 https://www.proquest.com/docview/3103449823 https://pubmed.ncbi.nlm.nih.gov/PMC11387515 https://doaj.org/article/03779c5cc9264a67966bb74f4a5ef24d
Volume	6
WOSCitedRecordID	wos001307836400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2632-6140 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002504894 issn: 2632-6140 databaseCode: DOA dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2632-6140 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002504894 issn: 2632-6140 databaseCode: M~E dateStart: 20190101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2632-6140 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002504894 issn: 2632-6140 databaseCode: 7X7 dateStart: 20190701 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2632-6140 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002504894 issn: 2632-6140 databaseCode: BENPR dateStart: 20190701 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZg4cAFgXhld6mMhDggRZvE49eRoq64UC0IpN4i23FEkUhXTXelvfDbdyZOS4sQXLjk4Eyi8edxZhyPv2HsdeGkDnQ4RrWyyEEHkxt0O3kJkfYfHQSRik3o-dwsFvZir9QX5YQleuAE3FlBjHhBhmDRdTv666G819CCk7GtoKGvL0Y9e4sp-gYTMZexMG5jlkKd-R_fuxXaRAV5OpyCzgTbDtzRwNr_p1Dz94zJPRd0_og9HGNH_i7p_Jjdid0T9mlKRR44nSJaX0fuuoZfjtjzZiTQ3dxwFOlp7du49Q0fkrIo_xUf2GYU8h7fiTou-6fs6_nsy_sP-VgnIfdgYJNrBV4YpyrERzhRKqVLb6EIRayaIHxbxYhhhBPWR29sq4rKBXCiibF0rWzFM3bUrbr4gnHQHgMm53wRLIZqwUkLsi0gBNmgsMjYGwStHu28r4clhFD1gG5N6NYJ3Yy93eJaXybejL8JTwn5nSBRXg8NaAj1aAj1vwwhY6fbcfuln6BSxLq0ssrYq91tnEG0LeK6uLoaZASANRX27nka5p0mgugUMYjJmDkwgANVD-90y28DSzd2FdeCpTz-H507YQ-S6dKJs1N2tFlfxZfsfrjeLPv1hN3VCz1czYTdm87mF58nw3zA68efs1slVw0v
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQYILDwElUMBIwAEpauJnfECIAlWrlhVIRdpbsB0HFolkSbZF-6f4jczksWUR6q0HrvHE8uPzzHg8D0KeJlZqj8ExqpRJLLTP4gzETpyKgO-PVnjeF5vQk0k2nZoPG-TXGAuDbpUjT-wYdVF7tJHvcCwqq1Mj2av5jxirRuHr6lhCo4fFYVj-hCtb-_LgLezvM8b23h2_2Y-HqgKxE5lYxFoJxzOrmLCKW54qpVNnROKTwArPXclCAKFruXHBZaZUCbNeWF6EkNpSlhz6vUQuAx_X6EKmp3pl08F0YJkRw-NpytWO-_6tqgGJTMR9SAyIMPi2JgS7WgH_UnD_9tP8Q_Dt3fjfluwmuT6o2PR1fyZukY1Q3SYfd7EWBsVgq-Y0UFsVdD5AlBZDnuHFkgJJiyaCwjZL2vmuoZsw_DA6XtIW-oRFnbV3yKcLmcVdslnVVbhHqNAO9EprXeINaLTeSiNkmQjvZQHEPCLPYZfzgR20eXfT4irv4JAjHPIeDhF5MQIhn_fpRc4j3kWorAgxM3j3oW6-5AOjyRPMIOml9wZUXYtWQuWcFqWwMpRMFBHZHsFyNr4zpETkyaoZGA2-Htkq1CcdDRfCZAxmt9XjcjUSjlknQdeLSLaG2LWhrrdUs69dMnOYKlyZU3n__HE9Jlf3j98f5UcHk8MH5Fp_ojD8bptsLpqT8JBc8aeLWds86o4kJZ8vGtC_AXS5dMM
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLUJceIhXoICRgANStIlfiQ8IsbQrqqLVgkDqLdiOA4tEsiTbov1r_DrGeWxZhHrrgWs8sfz4PDMezwPgaaRFYn1wjCxEFPLEpmGKYieMufPvj5pb1hWbSGaz9PhYzXfg1xAL490qB57YMuq8st5GPma-qGwSK0HHRe8WMd-fvlr-CH0FKf_SOpTT6CBy5NY_8frWvDzcx71-Run04OObt2FfYSA0POWrMJHcsFRLyrVkmsVSJrFRPLKRo7llpqDOoQDWTBlnUlXIiGrLNcudi3UhCob9XoLdBJUMMYLdycFs_mFj4fHJwVLF-6fUmMmx-f6trBCXlIddgAwKNPy2JRLbygH_Unf_9tr8QwxOr__PC3gDrvXKN3ndnZabsOPKW_B-4qtkEB-GVZ86osucLHvwkrzPQLxaEyRpvPEg1_WatF5t3oEYfxhcMkmDfeICL5rb8OlCZnEHRmVVuntAeGIQDFqbyCrUda0Wiosi4taKHIlZAM9xx7OeUTRZewdjMmuhkXloZB00AngxgCJbdolHziOeeNhsCH3O8PZDVX_JehaURT63pBXWKlSCtbcfSmMSXnAtXEF5HsDeAJyz8Z2hJoAnm2ZkQf5dSZeuOmlpGOcqpTi7ux1GNyNhPh8laoEBpFvo3Rrqdku5-NqmOcep4mU6FvfPH9djuII4zt4dzo4ewNXucPm4vD0YreoT9xAu29PVoqkf9eeTwOeLRvRvAfh-4w
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brain+reserve+and+physical+disability+in+secondary+progressive+multiple+sclerosis&rft.jtitle=BMJ+neurology+open&rft.au=John%2C+Nevin&rft.au=Li%2C+Yingtong&rft.au=De+Angelis%2C+Floriana&rft.au=Stutters%2C+Jonathan&rft.date=2024-09-07&rft.eissn=2632-6140&rft.volume=6&rft.issue=2&rft.spage=e000670&rft_id=info:doi/10.1136%2Fbmjno-2024-000670&rft_id=info%3Apmid%2F39262426&rft.externalDocID=39262426
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2632-6140&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2632-6140&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2632-6140&client=summon